IO Biotech



HBM contact: Dr Ivo Staijen, Dr Priyanka Belawat

Company status: public

Description - IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171